SPRO (Spero Therapeutics) Cash per Share: $0.97 (As of Mar. 2026)

What is Spero Therapeutics Cash per Share?

Spero Therapeutics SPRO -2.75% 55 Cash per Share is $0.97 as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Spero Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 was $0.97.

Spero Therapeutics (NAS:SPRO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Spero Therapeutics Cash per Share Related Terms

Spero Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Cash per Share Chart

Spero Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

4.52

2.08

1.44

0.97

0.71

Spero Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															0.88	0.56	0.86	0.71	0.97

55GF Score

Spero Therapeutics Inc SPRO

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spero Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Spero Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	40.265	/	56.42
	=	0.71

Spero Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	56.129	/	57.89
	=	0.97

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $0.97 mean?

Spero Therapeutics (SPRO) has a Cash per Share of $0.97 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Spero Therapeutics and its competitors.

Is Spero Therapeutics' Cash per Share too high?

Spero Therapeutics' current Cash per Share is $0.97. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Spero Therapeutics' Cash per Share compare to VXRT and ADCT?

Spero Therapeutics' Cash per Share of $0.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Spero Therapeutics and its competitors. Spero Therapeutics's current Cash per Share is $0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spero Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.12 — trading 101.9% above its estimated fair value. The current Cash per Share is $0.97. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Cash per Share is $0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.12 is trading 101.9% above its estimated GF Value™ of $1.05. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

Cash per Share: $0.97
GF Value™: $1.05 vs. price of $2.12 (101.9% above fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VXRT ADCT GNLX COYA AGEN VTVT LIXT SMNR CNTB ENLV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 2HA:Germany

Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

55GF Score

Get the complete analysis for SPRO

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.12

Price

$1.05

GF Value

View SPRO Analysis

See Cash per Share data for all stocks →